Small Compound Activators Of Hiv Latency

Latency reversal agents (LRA) have been identified that, when combined with current therapies targeting active virus, offer the potential of a functional cure for HIV.

Reservoirs of latent HIV virus are thought to be the major reason why traditional anti-retroviral therapies can chronically suppress viral load, but ultimately fail to completely rid the body of HIV.

Although current therapies can reduce HIV to undetectable levels, latent HIV virus continues to persist in hidden reservoirs within resting memory T cells. Once a patient stops the antiretroviral regimen, the latent virus rebounds in a matter of weeks.
Using a novel ex vivo model of HIV infection, a family of compounds has been identified for their ability to inhibit HIV latency. These LRAs specifically modulate HIV latency without causing massive activation or proliferation of immune system cells. The LRA mechanism likely operates through activation of a well-studied cell signaling pathway known as JAK/STAT. An LRA in combination with other anti-retroviral drugs has the potential to be a powerful treatment for the HIV positive population.

Lead Identified

• Reactive latent HIV reservoirs for combination with therapies which target active virus.
• Limits side-effects by preventing general T cell activation or differentiation
• Potential basis to eradicate HIV in infected patients. 

Sorensen, Eric S et al. “Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents.” Antimicrobial agents and chemotherapy vol. 64,8 e00888-20. 22 Jul. 2020, doi:10.1128/AAC.00888-20

Publication Number: US 2016/0151365 A1
Patent Title: Triazol-1-OL Analogs as Anti-Retroviral Latency Drugs
Jurisdiction/Country: United States
Application Type: Non-Provisional

Jason Young
(801) 587-0519
jason.r.young@utah.edu